30 Richmond Road
Homebush, NSW 2140
Australia
61 2 8415 7300
https://www.memphasys.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter:
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. David Ali | Acting CEO & Executive Director | 129,57k | N/A | N/A |
Pablo Neyertz | Director of Finance | 105,96k | N/A | N/A |
Associate Prof. Hassan Bakos | Director of Operations | 144,28k | N/A | N/A |
Prof. R. John Aitken Ph.D., ScD FRSE | Scientific Director | 151,37k | N/A | N/A |
Mr. Andrew Metcalfe B.Bus, CPA, FGIA, MAICD | Company Secretary | N/A | N/A | N/A |
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a device separates sperm from raw semen by electrophoresis process for use in human IVF procedures. In addition, the company's product pipeline include ROSA, a rapid oxidative stress assay; Samson Device, rapid equine pregnancy prediction assay; SemPort, a system that allows transport of semen; and AI-Port. Further, it provides ambient temperature storage product for human sperm. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.
Memphasys Limiteds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.